See accompanying report on pages 400-402.
Journal of American Association for Pediatric Ophthalmology and Strabismus
Volume 13, Issue 4, August 2009, Pages 329-331
EditorialExtrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern
References (24)
- et al.
Bevacizumab (avastin) for the treatment of ocular disease
Surv Ophthalmol
(2009) - et al.
Cerebrovascular accidents in ranibizumab
Ophthalmology
(2009) - et al.
Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients
Ophthalmology
(2007) - et al.
Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease
J AAPOS
(2008) - et al.
Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease
J AAPOS
(2009) - et al.
Intravitreal bevacizumab for idiopathic choroidal neovascularization
J AAPOS
(2009) - et al.
Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema
J AAPOS
(2009) - et al.
Pharmacokinetics of intravitreal bevacizumab (Avastin)
Ophthalmology
(2007) - et al.
Pharmacokinetics of intravitreal ranibizumab (Lucentis)
Ophthalmology
(2007) - et al.
Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration
Curr Opin Ophthalmol
(2009)
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration
Curr Opin Ophthalmol
(2009)
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration
Invest Ophthalmol Vis Sci
(2005)
Cited by (0)
Dr. Avery has received consulting or speaking fees from Alcon, Allergan, Genentech, Novartis, and Pfizer.
Copyright © 2009 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.